[go: up one dir, main page]

PE20050953A1 - Compuestos macrociclicos como inhibidores de la serina proteasa ns3 del virus de la hepatitis c - Google Patents

Compuestos macrociclicos como inhibidores de la serina proteasa ns3 del virus de la hepatitis c

Info

Publication number
PE20050953A1
PE20050953A1 PE2004000928A PE2004000928A PE20050953A1 PE 20050953 A1 PE20050953 A1 PE 20050953A1 PE 2004000928 A PE2004000928 A PE 2004000928A PE 2004000928 A PE2004000928 A PE 2004000928A PE 20050953 A1 PE20050953 A1 PE 20050953A1
Authority
PE
Peru
Prior art keywords
hepatitis
diona
virus
inhibitors
serine protease
Prior art date
Application number
PE2004000928A
Other languages
English (en)
Inventor
Francisco Velasquez
Srikanth Venkatraman
Jing Su
Patrick A Pinto
Viyyoor Girijavallabahn
Brian Mckittrick
Wanli Wu
F George Njoroge
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of PE20050953A1 publication Critical patent/PE20050953A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D245/00—Heterocyclic compounds containing rings of more than seven members having two nitrogen atoms as the only ring hetero atoms
    • C07D245/04—Heterocyclic compounds containing rings of more than seven members having two nitrogen atoms as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C04—CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
    • C04B—LIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
    • C04B35/00—Shaped ceramic products characterised by their composition; Ceramics compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
    • C04B35/622—Forming processes; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
    • C04B35/626—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B
    • C04B35/63—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B using additives specially adapted for forming the products, e.g.. binder binders
    • C04B35/632—Organic additives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0217—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -C(=O)-C-N-C(=O)-N-C-C(=O)-
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Ceramic Engineering (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Manufacturing & Machinery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Inorganic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Materials Engineering (AREA)
  • Structural Engineering (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

SE REFIERE A COMPUESTOS REPRESENTADOS POR LA ESTRUCTURA DE LA FORMULA (I), EN DONDE R1 ES -C(O)R5 O -B(OR)2; ; L' Y M' SON INDEPENDIENTEMENTE, H, ALQUILO, HETEROALQUILO, ARILO, ENTRE OTROS O JUNTOS SE UNEN PARA FORMAR UNA ESTRUCTURA ANULAR REPRESENTADA POR LA FORMULA 2, EN DONDE G Y J PUEDEN O NO ENCONTRARSE PRESENTES Y SE SELECCIONAN INDEPENDIENTEMENTE EN (CH2)p, (CHR)p, ENTRE OTROS; A Y M POEDEN O NO ENCONTRARSE PRESENTES E INDEPENDIENTEMENTE SON O, S, S(O)2, N(R), ENTRE OTROS; Z´ ES i) -(R77)CH2-CH(R44)-NH-CO-NH-, EN DONDE R44 ES TERT BUTIL, ISOPROPIL, FENILO, R77 ES UN RADICAL 1,3 DIONA -ISOINDOL, 2,5 DIONA PIRRODINIL, 1,3 DIONA HEXAHIDRO PIRROLO-PIRIDIL, ENTRE OTROS; ii) -(R79)-SO2-CH2-(CICLOALQUIL(C3-C6))-NH-CO-NH-, ENTRE OTROS; X ES -[(R29)CH]a-[R30C=CR30]b-(O)c-(S)d=(O)e-[(R29´)A]f-; D ES -[(R32)CH]g-(O)i=(C)h-(N)j-[(R33)A]k-(C=C)l-[(R34)CH]m-; O D Y X TOMADOS JUNTOS REPRESENTAN UNA CADENA CONECTORA NO RAMIFICADA PARAFINICA DIVALENTE DE (C7-C12) QUE FORMA UNA PORCION DE UN MACROCICLO DE 14 A 19 MIEMBROS, QUE POSEE UN GRADO SIMPLE DE INSATURACION. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA QUE ADEMAS PUEDEN COMPRENDER UN INTERFERON COMO ALFA INTERFERON O UN AGENTE ANTIVIRAL COMO RIBAVIRIN. ESTOS COMPUESTOS SON INHIBIDORES DE LA SERINA PROTEASA NS3/NS4a DEL VIRUS DE LA HEPATITIS C Y SON UTILES EN EL TRATAMIENTO DE LA HEPATITIS C Y TRANSTORNOS RELACIONADOS
PE2004000928A 2003-09-26 2004-09-23 Compuestos macrociclicos como inhibidores de la serina proteasa ns3 del virus de la hepatitis c PE20050953A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US50663703P 2003-09-26 2003-09-26

Publications (1)

Publication Number Publication Date
PE20050953A1 true PE20050953A1 (es) 2005-11-19

Family

ID=34393181

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2004000928A PE20050953A1 (es) 2003-09-26 2004-09-23 Compuestos macrociclicos como inhibidores de la serina proteasa ns3 del virus de la hepatitis c

Country Status (21)

Country Link
US (1) US7592419B2 (es)
EP (1) EP1664092B1 (es)
JP (2) JP4525982B2 (es)
KR (1) KR20060085248A (es)
CN (1) CN1894274A (es)
AR (1) AR046166A1 (es)
AT (1) ATE497505T1 (es)
AU (1) AU2004276281A1 (es)
BR (1) BRPI0414814A (es)
CA (1) CA2540031A1 (es)
CO (1) CO5680449A2 (es)
DE (1) DE602004031298D1 (es)
EC (1) ECSP066456A (es)
IL (1) IL174459A0 (es)
MX (1) MXPA06003455A (es)
NO (1) NO20061822L (es)
PE (1) PE20050953A1 (es)
RU (1) RU2006113880A (es)
TW (1) TWI280964B (es)
WO (1) WO2005030796A1 (es)
ZA (1) ZA200602447B (es)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN183120B (es) 1996-10-18 1999-09-11 Vertex Pharma
US7176208B2 (en) 2003-04-18 2007-02-13 Enanta Pharmaceuticals, Inc. Quinoxalinyl macrocyclic hepatitis C serine protease inhibitors
US20110150835A1 (en) * 2003-09-26 2011-06-23 Schering Corporation Macrocyclic Inhibitors of Hepatitis C Virus NS3 Serine Protease
EP1919478B1 (en) * 2005-06-02 2016-03-23 Merck Sharp & Dohme Corp. Combination of hcv protease inhibitors with a surfactant
US20070237818A1 (en) * 2005-06-02 2007-10-11 Malcolm Bruce A Controlled-release formulation of HCV protease inhibitor and methods using the same
NZ563361A (en) 2005-06-02 2011-02-25 Schering Corp HCV protease inhibitors in combination with food
BRPI0613962A2 (pt) * 2005-07-25 2009-03-24 Intermune Inc inibidores macrocìclicos inovadores de replicação de vìrus da hepatite c
US8399615B2 (en) * 2005-08-19 2013-03-19 Vertex Pharmaceuticals Incorporated Processes and intermediates
BRPI0615029A2 (pt) * 2005-08-19 2009-06-16 Vertex Pharma processos e intermediários
AR055395A1 (es) 2005-08-26 2007-08-22 Vertex Pharma Compuestos inhibidores de la actividad de la serina proteasa ns3-ns4a del virus de la hepatitis c
DK1999129T3 (da) * 2005-10-11 2011-02-07 Intermune Inc Forbindelser og fremgangsmåder til inhibering af replikationen af hepatitis C-virus
US7705138B2 (en) * 2005-11-11 2010-04-27 Vertex Pharmaceuticals Incorporated Hepatitis C virus variants
JP5409008B2 (ja) 2005-11-11 2014-02-05 バーテックス ファーマシューティカルズ インコーポレイテッド Ｃ型肝炎ウイルス改変体
US7816348B2 (en) 2006-02-03 2010-10-19 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
US9526769B2 (en) * 2006-06-06 2016-12-27 Enanta Pharmaceuticals, Inc. Macrocylic oximyl hepatitis C protease inhibitors
AR061629A1 (es) * 2006-06-26 2008-09-10 Enanta Pharm Inc Quinoxalinil macrociclicos inhibidores de serina proteasa del virus de la hepatitis c. proceso de obtencion y composiciones farmaceuticas
CN101674844A (zh) * 2006-08-04 2010-03-17 英安塔制药有限公司 四唑基大环类c型肝炎丝氨酸蛋白酶抑制剂
US7662779B2 (en) * 2006-08-11 2010-02-16 Enanta Pharmaceuticals, Inc. Triazolyl macrocyclic hepatitis C serine protease inhibitors
MX2009000882A (es) 2006-08-17 2009-02-04 Boehringer Ingelheim Int Inhibidores de la polimerasa virica.
US8003604B2 (en) * 2006-11-16 2011-08-23 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US20100120716A1 (en) * 2006-12-06 2010-05-13 Phenomix Corporation Macrocyclic hepatitis c serine protease inhibitors and uses therefor
US20100081672A1 (en) * 2006-12-07 2010-04-01 Schering Corporation Ph sensitive matrix formulation
PL2118098T3 (pl) * 2007-02-01 2015-03-31 Janssen Sciences Ireland Uc Postacie polimorficzne makrocyklicznego inhibitora HCV
BRPI0807887A2 (pt) * 2007-02-20 2014-06-17 Novartis Ag Compostos macrocíclicos como inibidores de hcv ns3 protease.
US20090005387A1 (en) * 2007-06-26 2009-01-01 Deqiang Niu Quinoxalinyl macrocyclic hepatitis c virus serine protease inhibitors
EP2188274A4 (en) 2007-08-03 2011-05-25 Boehringer Ingelheim Int VIRAL POLYMERASE HEMMER
US8268777B2 (en) * 2007-12-05 2012-09-18 Enanta Pharmaceuticals, Inc. Oximyl macrocyclic derivatives
WO2009079352A1 (en) * 2007-12-14 2009-06-25 Enanta Pharmaceuticals, Inc. Macrocyclic oximyl hepatitis c serine protease inhibitors
US8476257B2 (en) 2007-12-19 2013-07-02 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
US8372802B2 (en) * 2008-03-20 2013-02-12 Enanta Pharmaceuticals, Inc. Fluorinated macrocyclic compounds as hepatitis C virus inhibitors
WO2009142842A2 (en) * 2008-04-15 2009-11-26 Intermune, Inc. Novel macrocyclic inhibitors of hepatitis c virus replication
US20090285773A1 (en) * 2008-05-15 2009-11-19 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
CN101580535B (zh) * 2008-05-16 2012-10-03 太景生物科技股份有限公司 丙型肝炎病毒蛋白酶抑制剂
CN102046648A (zh) * 2008-05-29 2011-05-04 百时美施贵宝公司 丙型肝炎病毒抑制剂
UY32099A (es) 2008-09-11 2010-04-30 Enanta Pharm Inc Inhibidores macrocíclicos de serina proteasas de hepatitis c
AU2009303483A1 (en) * 2008-10-15 2010-04-22 Intermune, Inc. Therapeutic antiviral peptides
US20100272674A1 (en) * 2008-12-04 2010-10-28 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
MX2011007195A (es) 2009-01-07 2013-07-12 Scynexis Inc Derivado de ciclosporina para el uso en el tratamiento de infección de virus de hepatitis c (vhc) y virus de inmunodeficiencia humana (vih).
EP2435424B1 (en) 2009-05-29 2015-01-21 Merck Sharp & Dohme Corp. Antiviral compounds composed of three linked aryl moieties to treat diseases such as hepatitis c
US8232246B2 (en) * 2009-06-30 2012-07-31 Abbott Laboratories Anti-viral compounds
US8389560B2 (en) * 2009-09-15 2013-03-05 Taigen Biotechnology Co., Ltd. HCV protease inhibitors
TW201116540A (en) * 2009-10-01 2011-05-16 Intermune Inc Therapeutic antiviral peptides
US20120276047A1 (en) 2009-11-25 2012-11-01 Rosenblum Stuart B Fused tricyclic compounds and derivatives thereof useful for the treatment of viral diseases
EP2516430B1 (en) 2009-12-22 2014-11-05 Merck Sharp & Dohme Corp. Fused tricyclic compounds and methods of use thereof for the treatment of viral diseases
US20110178107A1 (en) * 2010-01-20 2011-07-21 Taigen Biotechnology Co., Ltd. Hcv protease inhibitors
BR112012022125A2 (pt) 2010-03-09 2016-11-01 Merck Sharp & Dhme Corp composto, sal de dicloridrato, composição farmacêutica, uso do composto, e, método para tratar um paciente
JP2013541499A (ja) 2010-07-26 2013-11-14 メルク・シャープ・エンド・ドーム・コーポレイション 置換されたビフェニレン化合物およびウイルス性疾患の治療のためのその使用方法
AU2011314168A1 (en) 2010-09-29 2013-04-04 Merck Sharp & Dohme Corp. Fused tetracycle derivatives and methods of use thereof for the treatment of viral diseases
MX2013007677A (es) 2010-12-30 2013-07-30 Abbvie Inc Inhibidores macrociclicos de serina proteasa de hepatitis.
KR20140003521A (ko) 2010-12-30 2014-01-09 이난타 파마슈티칼스, 인코포레이티드 페난트리딘 매크로사이클릭 ｃ형 간염 세린 프로테아제 억제제
ES2742299T3 (es) 2011-03-09 2020-02-13 Jitsubo Co Ltd Nuevos péptidos entrecruzados que contienen una estructura entrecruzada no peptídica, método para sintetizar péptidos entrecruzados y nuevo compuesto orgánico utilizado en el método
WO2012142075A1 (en) 2011-04-13 2012-10-18 Merck Sharp & Dohme Corp. 2'-azido substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
EA201391519A1 (ru) 2011-04-13 2014-03-31 Мерк Шарп И Доум Корп. 2'-замещенные нуклеозидные производные и способы их применения для лечения вирусных заболеваний
US10201584B1 (en) 2011-05-17 2019-02-12 Abbvie Inc. Compositions and methods for treating HCV
WO2013033899A1 (en) 2011-09-08 2013-03-14 Merck Sharp & Dohme Corp. Substituted benzofuran compounds and methods of use thereof for the treatment of viral diseases
WO2013033901A1 (en) 2011-09-08 2013-03-14 Merck Sharp & Dohme Corp. Heterocyclic-substituted benzofuran derivatives and methods of use thereof for the treatment of viral diseases
WO2013033900A1 (en) 2011-09-08 2013-03-14 Merck Sharp & Dohme Corp. Tetracyclic heterocycle compounds and methods of use thereof for the treatment of viral diseases
EP2755981A4 (en) 2011-09-14 2015-03-25 Merck Sharp & Dohme SILICULAR HETEROCYCLIC DERIVATIVES AND METHOD FOR THEIR USE FOR THE TREATMENT OF VIRUS DISEASES
CN102617705B (zh) * 2012-02-16 2014-12-31 上海纬诺医药科技有限公司 抑制丙肝病毒复制的大环类化合物
US9365615B2 (en) 2013-09-09 2016-06-14 Jitsubo Co., Ltd. Cross-linked peptides containing non-peptide cross-linked structure, method for synthesizing cross-linked peptides, and novel organic compound used in method
US10167298B2 (en) 2013-10-30 2019-01-01 Merck Sharp & Dohme Corp. Pseudopolymorphs of an HCV NS5A inhibitor and uses thereof
WO2015103490A1 (en) 2014-01-03 2015-07-09 Abbvie, Inc. Solid antiviral dosage forms
US12083099B2 (en) 2020-10-28 2024-09-10 Accencio LLC Methods of treating symptoms of coronavirus infection with viral protease inhibitors

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1049686C (zh) 1987-11-18 2000-02-23 希龙股份有限公司 非ａ和非ｂ肝炎病毒的诊断及疫苗
US5698390A (en) 1987-11-18 1997-12-16 Chiron Corporation Hepatitis C immunoassays
DE69133617D1 (de) 1990-04-04 2009-07-23 Novartis Vaccines & Diagnostic Protease von Hepatitis C Virus
US5922757A (en) 1996-09-30 1999-07-13 The Regents Of The University Of California Treatment and prevention of hepatic disorders
IN183120B (es) 1996-10-18 1999-09-11 Vertex Pharma
GB9623908D0 (en) 1996-11-18 1997-01-08 Hoffmann La Roche Amino acid derivatives
PT1012180E (pt) 1997-08-11 2005-04-29 Boehringer Ingelheim Ca Ltd Analogos de peptidos inibidores da hepatite c
US6323180B1 (en) * 1998-08-10 2001-11-27 Boehringer Ingelheim (Canada) Ltd Hepatitis C inhibitor tri-peptides
AR022061A1 (es) 1998-08-10 2002-09-04 Boehringer Ingelheim Ca Ltd Peptidos inhibidores de la hepatitis c, una composicion farmaceutica que los contiene, el uso de los mismos para preparar una composicion farmaceutica, el uso de un producto intermedio para la preparacion de estos peptidos y un procedimiento para la preparacion de un peptido analogo de los mismos.
UA74546C2 (en) * 1999-04-06 2006-01-16 Boehringer Ingelheim Ca Ltd Macrocyclic peptides having activity relative to hepatitis c virus, a pharmaceutical composition and use of the pharmaceutical composition
JP4806154B2 (ja) 2000-04-03 2011-11-02 バーテックス ファーマシューティカルズ インコーポレイテッド セリンプロテアーゼ、特にｃ型肝炎ウイルスｎｓ３プロテアーゼのインヒビター
NZ521455A (en) 2000-04-05 2004-06-25 Schering Corp Macrocyclic NS3-Serine protease inhibitors of hepatitis C virus comprising N-Cyclic P2 Moieties
BR0110104A (pt) 2000-04-19 2003-01-07 Schering Corp Inibidores de ns-3 serina rotease macrocìclica do vìrus da hepatite c compreendendo porções de alquil e aril alanina p2
MY139078A (en) 2000-07-21 2009-08-28 Schering Corp Peptides as ns3-serine protease inhibitors of hepatitis c virus
AR034127A1 (es) 2000-07-21 2004-02-04 Schering Corp Imidazolidinonas como inhibidores de ns3-serina proteasa del virus de hepatitis c, composicion farmaceutica, un metodo para su preparacion, y el uso de las mismas para la manufactura de un medicamento
AR029851A1 (es) 2000-07-21 2003-07-16 Dendreon Corp Nuevos peptidos como inhibidores de ns3-serina proteasa del virus de hepatitis c
WO2002008187A1 (en) * 2000-07-21 2002-01-31 Schering Corporation Novel peptides as ns3-serine protease inhibitors of hepatitis c virus
WO2002008251A2 (en) 2000-07-21 2002-01-31 Corvas International, Inc. Peptides as ns3-serine protease inhibitors of hepatitis c virus
US7244721B2 (en) * 2000-07-21 2007-07-17 Schering Corporation Peptides as NS3-serine protease inhibitors of hepatitis C virus
EP1343807B1 (en) 2000-12-12 2009-04-29 Schering Corporation Diaryl peptides as ns3-serine protease inhibitors of hepatits c virus
TWI265927B (en) * 2002-01-23 2006-11-11 Schering Corp Novel compounds as NS3-serine protease inhibitors of hepatitis C virus
WO2004072243A2 (en) 2003-02-07 2004-08-26 Enanta Pharmaceuticals, Inc. Macrocyclic hepatitis c serine protease inhibitors
PL1615613T3 (pl) * 2003-04-18 2010-04-30 Enanta Pharm Inc Chinoksalinylowe makrocykliczne inhibitory proteazy serynowej zapalenia wątroby typu C

Also Published As

Publication number Publication date
NO20061822L (no) 2006-06-22
CO5680449A2 (es) 2006-09-29
BRPI0414814A (pt) 2006-11-14
CN1894274A (zh) 2007-01-10
US7592419B2 (en) 2009-09-22
MXPA06003455A (es) 2006-05-31
ATE497505T1 (de) 2011-02-15
ZA200602447B (en) 2007-09-26
IL174459A0 (en) 2006-08-01
KR20060085248A (ko) 2006-07-26
AU2004276281A1 (en) 2005-04-07
ECSP066456A (es) 2006-09-18
TW200526687A (en) 2005-08-16
DE602004031298D1 (de) 2011-03-17
CA2540031A1 (en) 2005-04-07
WO2005030796A1 (en) 2005-04-07
AR046166A1 (es) 2005-11-30
JP4525982B2 (ja) 2010-08-18
EP1664092B1 (en) 2011-02-02
JP2009275048A (ja) 2009-11-26
TWI280964B (en) 2007-05-11
US20050119168A1 (en) 2005-06-02
EP1664092A1 (en) 2006-06-07
JP2007534627A (ja) 2007-11-29
RU2006113880A (ru) 2007-11-20

Similar Documents

Publication Publication Date Title
PE20050953A1 (es) Compuestos macrociclicos como inhibidores de la serina proteasa ns3 del virus de la hepatitis c
NO20062428L (no) Kombinasjoner for HCV-behandling
CY1109216T1 (el) Πεπτιδομιμητικοι αναστολεις πρωτεασης
ATE539744T1 (de) Hemmer von serin-protease, insbesondere von hepatitis-c-virus-ns3-ns4a-protease, mit einem kondensierten ringsystem
TW200621233A (en) HCV NS3-NS4A protease inhibition
UY28500A1 (es) Inhibidores de proteasas de serina, en particular proteasa ns3-ns4a del vhc.
CY1109385T1 (el) Αναστολεις γυρασης και χρησεις αυτων
UY28323A1 (es) Compuestos inhibidores de la hepatitis c
CY1113809T1 (el) Μακροκυκλικα καρβοξυλικα οξεα και ακυλοσουλφοναμιδικες ενωσεις ως αναστολεις της αντιγραφης του hcv
CY1109671T1 (el) Αναστολεις της πρωτεασης ns3 του hcv
EA200600498A1 (ru) Макроциклические пептиды, проявляющие противовирусную активность в отношении вируса гепатита с
ATE481106T1 (de) Heterocyclische sulfonamid-hepatitis-c-virus- hemmer
EP1771454A4 (en) PEPTIDE ANALOGUE AS HEPATITIS C HEMMER
PE20051150A1 (es) Compuestos azufrados como inhibidores de la serina proteasa ns3 del virus de la hepatitis c
ECSP034642A (es) Derivados de tetralona como agentes antitumorales
EA200400886A1 (ru) Макроциклические пептиды, обладающие активностью в отношении вируса гепатита c
EA200900969A1 (ru) Макроциклические ингибиторы протеазы гепатита с
CO5700767A2 (es) Procedimiento de tratamiento de rechazo de transplantes
CY1107084T1 (el) Παραγωγα πυρρολοπυριδαζινης
ES2240446T3 (es) Inhibidores de serina proteasas, particularmente la proteasa ns3 del virus de la hepatitis c.
ATE413411T1 (de) Substituierte cycloalkyl p1' hepatitis c virus inhibitoren
RU2007104028A (ru) Ингибиторы iap
EA200500584A1 (ru) Нуклеозидные производные для лечения инфекционных заболеваний, вызванных вирусом гепатита c
TNSN06071A1 (en) Use of modified cyclosporins for the treatment of hcv disorders
CY1108874T1 (el) ΧΡΗΣΗ ΤΩΝ ΑΝΑΣΤΟΛΕΩΝ Ι κΒ- ΚΙΝΑΣΗΣ ΣΤΗ ΘΕΡΑΠΕΙΑ ΤΟΥ ΠΟΝΟΥ

Legal Events

Date Code Title Description
FC Refusal